[Polatuzumab vedotin (combination with rituximab, cyclophosphamide, doxorubicin and prednisone for DLBCL – Benefit assessment according to § 35a Social Code Book V]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018011987
German
Original Title: Polatuzumab Vedotin (Kombination mit Rituximab, Cyclophosphamid, Doxorubicin und Prednison; bisher unbehandeltes DLBCL)
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/a23-141.html
Year Published: 2024
URL for published report: https://www.iqwig.de/download/a23-141_polatuzumab-vedotin_nutzenbewertung-35a-sgb-v_v1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
DOI: https://doi.org/10.60584/A23-141
MeSH Terms
  • Lymphoma, Large B-Cell, Diffuse
  • Rituximab
  • Cyclophosphamide
  • Doxorubicin
  • Prednisone
  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Immunoconjugates
Keywords
  • Polatuzumab Vedotin
  • Lymphoma – Large B-Cell – Diffuse
  • Benefit Assessment
  • NCT03274492
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.